Use of MIF and MIF pathway agonists
AssigneeYale University
InventorsRichard Bucala, Lawrence H. Young
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel methods and compositions for increasing AMPK activity and glucose uptake comprising administering a macrophage migration inhibitory factor (MIF) pathway agonist in a subject in need thereof. The invention also relates to methods for selecting a subject for treatment with an agonist of MIF, identifying a subject at risk for developing a condition in which increased AMPK activity is desirable, and for predicting whether a subject is susceptible to a condition in which increased AMPK activity is desirable.
Claims2
A method of increasing uptake of AMPK-mediated glucose into a cell, comprising administering a MIF agonist to a subject in need thereof,
- wherein the MIF agonist increases the uptake of AMPK-mediated glucose into the cell;
- and
- wherein the subject has a condition in which increased AMPK activity is desirable selected from the group consisting of hypoxia, ischemia, and type 2 diabetes.
A method of increasing AMPK-mediated glycolysis in a cell, comprising administering a MIF agonist to a subject in need thereof,
- wherein the MIF agonist increases the AMPK-mediated glycolysis in the cell;
- and
- wherein the subject has a condition in which increased AMPK activity is desirable selected from the group consisting of:
- hypoxia, ischemia, and type 2 diabetes.
Dependencies are inferred from the claim text.